Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03606837
Overview
Patients with primary intermediate risk prostate cancer for whom radical prostatectomy is indicated, will be invited to participate to the present study. Positron Emission Tomography coupled with scanner (PET-CT) using a radiotracer : 68Ga-RM2 and Positron Emission Tomography coupled with scanner (PET-CT) using another radiotracer : 68Ga-PSMA-617, will be scheduled.
Sponsor
University Hospital, Bordeaux
Phase
Phase 2
Contacts
Henri CLERMONT-GALLERANDE (Principal Investigator)
henri.de-clermont-galleran@chu-bordeaux.fr
05 56 79 55 40
Clément MORGAT
clement.morgat@chu-bordeaux.fr
05 56 79 55 40
ClinicalTrials.gov
NCT03606837Drug / Compound
Help us improve your experience